LEE011 (ribociclib, a selective cyclin dependent kinase inhibitor developed by Novartis, was granted Priority Review by FDA. FDA also accepted Novartis’s new Drug Application for filing as first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer in combination with letrozole. The NDA is based on...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
